BRPI0720635A2 - Compostos orgânicos e seus usos - Google Patents

Compostos orgânicos e seus usos Download PDF

Info

Publication number
BRPI0720635A2
BRPI0720635A2 BRPI0720635-6A BRPI0720635A BRPI0720635A2 BR PI0720635 A2 BRPI0720635 A2 BR PI0720635A2 BR PI0720635 A BRPI0720635 A BR PI0720635A BR PI0720635 A2 BRPI0720635 A2 BR PI0720635A2
Authority
BR
Brazil
Prior art keywords
substituted
unsubstituted
alkyl
group
compound
Prior art date
Application number
BRPI0720635-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Rohan Eric John Beckwith
Daniel Tim Curtis
Edmund Harrington
Jurgen Hans-Hermann Hinrichs
John Anthony Tallarico
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0720635A2 publication Critical patent/BRPI0720635A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0720635-6A 2006-12-22 2007-12-20 Compostos orgânicos e seus usos BRPI0720635A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87147106P 2006-12-22 2006-12-22
US60/871,471 2006-12-22
PCT/US2007/088292 WO2008079933A2 (en) 2006-12-22 2007-12-20 Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections

Publications (1)

Publication Number Publication Date
BRPI0720635A2 true BRPI0720635A2 (pt) 2014-01-07

Family

ID=39367530

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720635-6A BRPI0720635A2 (pt) 2006-12-22 2007-12-20 Compostos orgânicos e seus usos

Country Status (11)

Country Link
US (1) US20100048597A1 (enExample)
EP (1) EP2094682A2 (enExample)
JP (1) JP2010514689A (enExample)
KR (1) KR20090091306A (enExample)
CN (1) CN101568529A (enExample)
AU (1) AU2007336933A1 (enExample)
BR (1) BRPI0720635A2 (enExample)
CA (1) CA2672518A1 (enExample)
EA (1) EA200900799A1 (enExample)
MX (1) MX2009006536A (enExample)
WO (1) WO2008079933A2 (enExample)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019524B1 (ru) * 2007-05-04 2014-04-30 Айрм Ллк СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ с-kit И PDGFR
EP2200436B1 (en) * 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
JP2012504646A (ja) * 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
BRPI0914360A2 (pt) * 2008-11-14 2015-08-11 Bayer Cropscience Ag Derivado de piridil-azinilamino substituído, composto da fórmula (i), composição fungicida, método para controlar fungos fitopatogênicos de culturas e método para combater fungos fitopatogênicos e/ou micotoxinas
CA2761896A1 (en) 2009-05-13 2010-11-18 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
CN102471310A (zh) * 2009-09-04 2012-05-23 诺瓦提斯公司 用于治疗增生性疾病的联吡啶化合物
CN102482265A (zh) * 2009-09-04 2012-05-30 诺瓦提斯公司 用于治疗增殖性疾病的吡嗪基吡啶化合物
US20120277244A1 (en) * 2009-12-31 2012-11-01 Novartis Ag Pyrazine derivatives and their use in the treatment of neurological disorders
CN102933561B (zh) * 2010-03-22 2016-05-11 利德发现中心有限责任公司 具有药学活性的二取代三嗪衍生物
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
EA201390717A1 (ru) * 2010-11-17 2013-10-30 Новартис Аг 3-(аминоарил)пиридиновые соединения
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2012101065A2 (en) 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101013A1 (en) * 2011-01-28 2012-08-02 Boehringer Ingelheim International Gmbh Substituted pyridinyl-pyrimidines and their use as medicaments
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
US20130303507A1 (en) * 2011-01-28 2013-11-14 Novartis Ag Substituted hetero-biaryl compounds and their uses
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
JP5947818B2 (ja) * 2011-03-02 2016-07-06 リード ディスカバリー センター ゲーエムベーハー 薬学的活性化二置換ピリジン誘導体
WO2012117048A1 (en) * 2011-03-02 2012-09-07 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
CA2833288A1 (en) * 2011-04-19 2012-10-26 Bayer Intellectual Property Gmbh Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
TWI555737B (zh) * 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
KR101979042B1 (ko) 2011-08-04 2019-05-15 어레이 바이오파마 인크. 세린/트레오닌 키나제 억제제로서의 퀴나졸린 화합물
EP2561867A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH CDK9 inhibitors in the treatment of midline carcinoma
EP2562265A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Susceptibility to selective CDK9 inhibitors
JP5976814B2 (ja) * 2011-09-16 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ スルホキシイミン基を含有する二置換５−フルオロピリミジン誘導体
EP2755956B1 (en) * 2011-09-16 2016-05-18 Bayer Intellectual Property GmbH 2,4-disubstituted 5-fluoro-pyrimidines as selective cdk9 inhibtors
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
DK3321262T3 (da) 2012-03-01 2021-01-25 Array Biopharma Inc Serin-/threoninkinasehæmmere
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US8901305B2 (en) * 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
CA2880477A1 (en) * 2012-08-23 2014-02-27 F. Hoffmann-La Roche Ag Novel phenyl-pyridine/pyrazine amides for the treatment of cancer
JP6378182B2 (ja) 2012-08-27 2018-08-22 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性│疾患の処置のためのセリン／スレオニンキナーゼ阻害剤
EP2900665B1 (en) * 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
ES2595222T3 (es) 2012-10-18 2016-12-28 Bayer Pharma Aktiengesellschaft Derivados de 5-fluoro-N-(piridin-2-il)piridin-2-amina que contienen un grupo sulfona
CA2888381A1 (en) 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
CA2888383A1 (en) 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
SG11201503079PA (en) 2012-11-15 2015-06-29 Bayer Pharma AG 5-FLUORO-<i>N</i>-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP
EA035349B1 (ru) 2012-11-21 2020-05-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9527857B2 (en) 2013-03-15 2016-12-27 GI Therapeutics, Inc. HSPC-sparing treatments for RB-positive abnormal cellular proliferation
US20140271460A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly Active Anti-Neoplastic and Anti-Proliferative Agents
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
CA2917096C (en) 2013-07-04 2021-05-18 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
WO2015030847A1 (en) 2013-08-30 2015-03-05 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
TW201605857A (zh) * 2013-10-03 2016-02-16 赫孚孟拉羅股份公司 Ｃｄｋ８之醫療性抑制劑及其用途
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CN105916848B (zh) * 2013-12-31 2018-01-09 山东轩竹医药科技有限公司 激酶抑制剂及其用途
US9949976B2 (en) 2013-12-31 2018-04-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
EP3094326A4 (en) 2014-01-14 2017-07-26 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TN2016000270A1 (en) 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
CA2942119A1 (en) 2014-03-13 2015-09-17 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
US9790189B2 (en) 2014-04-01 2017-10-17 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
CN106459084B (zh) 2014-04-11 2019-04-19 拜耳医药股份有限公司 大环化合物
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3206749B1 (en) 2014-10-14 2021-09-08 The Regents of the University of California The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
EP3207037B1 (en) 2014-10-16 2019-01-23 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
CA2964696C (en) 2014-10-16 2022-09-06 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
WO2016150902A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
WO2016150893A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma
WO2016150903A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas
CN106188029B (zh) * 2015-05-05 2018-09-18 山东轩竹医药科技有限公司 二并环类间变性淋巴瘤激酶抑制剂
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
EP3356373B1 (en) 2015-09-29 2020-02-19 Bayer Pharma Aktiengesellschaft Novel macrocyclic sulfondiimine compounds
CN108368129B (zh) 2015-10-08 2021-08-17 拜耳医药股份有限公司 改性大环化合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MX2019006523A (es) 2016-12-05 2019-10-15 G1 Therapeutics Inc Conservacion de respuesta inmunitaria durante regimenes de quimioterapia.
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN109985241B (zh) * 2017-12-29 2024-10-18 广州威溶特医药科技有限公司 Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
CN110041253B (zh) * 2018-01-17 2022-03-29 上海翰森生物医药科技有限公司 吡啶类n-氧化衍生物及其制备方法和应用
CN111727183B (zh) 2018-02-13 2023-12-29 拜耳公司 5-氟-4-(4-氟-2-甲氧基苯基)-n-{4-[(s-甲基磺亚胺酰基)甲基]吡啶-2-基}吡啶-2-胺用于治疗弥漫性大b细胞淋巴瘤中的用途
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
ES2991427T3 (es) 2018-05-04 2024-12-03 Incyte Corp Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
AU2019340402B2 (en) 2018-08-17 2025-04-03 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
US20220048888A1 (en) * 2018-09-12 2022-02-17 Genentech, Inc. Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use
WO2020125513A1 (zh) 2018-12-19 2020-06-25 凯复制药有限公司 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
TWI748317B (zh) 2019-01-03 2021-12-01 美商建南德克公司 吡啶并－嘧啶酮與喋啶酮化合物及使用方法
CN109678962B (zh) * 2019-01-22 2020-05-08 山西农业大学 一种Cdk5纳米抗体和筛选方法
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN109836385B (zh) * 2019-04-04 2021-12-17 上海翰森生物医药科技有限公司 四氢喹啉类n-氧化衍生物及其制备方法和应用
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN110511211B (zh) * 2019-08-30 2020-10-16 武汉工程大学 一种吲唑哌啶嘧啶类化合物的应用
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN111349624A (zh) * 2020-03-20 2020-06-30 深圳大学 核酸、多肽偶联组合物、多肽组合物及其制备方法和应用
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
JP7537002B2 (ja) * 2020-08-07 2024-08-20 南京薬石科技股▲フン▼有限公司 Ｃｄｋ９阻害剤およびその使用
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
KR102693170B1 (ko) * 2021-04-27 2024-08-08 재단법인 아산사회복지재단 사이클린 의존성 키나아제 억제용 조성물 및 이의 의학적 용도
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN117384135A (zh) * 2022-07-04 2024-01-12 浙江同源康医药股份有限公司 用作cdk7激酶抑制剂的化合物及其应用
CN119841771B (zh) * 2025-01-08 2026-02-13 华中农业大学 一种猪链球菌丝氨酸蛋白激酶抑制剂的筛选方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788195A (en) * 1986-01-13 1988-11-29 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
EP0233461B2 (en) * 1986-01-13 2002-05-29 American Cyanamid Company 4,5,6-Substituted-2-pyrimidinamines
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
WO1998028281A1 (en) * 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
US6469018B1 (en) * 1999-01-08 2002-10-22 Smithkline Beecham Corporation Compounds
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
EP1373257B9 (en) * 2001-03-29 2008-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1533304B1 (en) * 2002-06-28 2009-11-04 Nippon Shinyaku Co., Ltd. Amide derivative
GB0226724D0 (en) * 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
SE0203654D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab New compounds
WO2004078682A2 (en) * 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
GB0307268D0 (en) * 2003-03-28 2003-05-07 Syngenta Ltd Organic compounds
WO2005065074A2 (en) * 2003-09-09 2005-07-21 Temple University Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
DK1702917T3 (da) * 2003-12-25 2017-11-13 Nippon Shinyaku Co Ltd Amidderivat og medicin
MXPA06012613A (es) * 2004-05-07 2007-01-31 Amgen Inc Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
JP2008510766A (ja) * 2004-08-27 2008-04-10 ゲーペーツェー ビオテック アーゲー ピリミジン誘導体
EP2471529A3 (en) * 2006-09-05 2012-10-10 Emory University Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof

Also Published As

Publication number Publication date
JP2010514689A (ja) 2010-05-06
AU2007336933A1 (en) 2008-07-03
WO2008079933A2 (en) 2008-07-03
MX2009006536A (es) 2009-06-26
KR20090091306A (ko) 2009-08-27
CA2672518A1 (en) 2008-07-03
EA200900799A1 (ru) 2009-12-30
CN101568529A (zh) 2009-10-28
EP2094682A2 (en) 2009-09-02
WO2008079933A3 (en) 2008-12-04
US20100048597A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
BRPI0720635A2 (pt) Compostos orgânicos e seus usos
US20100093776A1 (en) Organic Compounds and Their Uses
CN103124730B (zh) 杂环炔苯类化合物及其药用组合物和应用
EP1562938B1 (en) Heteroaryl-pyrimidine derivatives as jak inhibitors
US9969710B2 (en) Heteroaryl compounds as IRAK inhibitors and uses thereof
CN100491371C (zh) 用作糖原合酶激酶3β抑制剂(GSK3抑制剂)的杂芳胺化合物
JP5752232B2 (ja) プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
BR112021008991A2 (pt) derivados de 2,3-di-hidro-1h-pirrolo [3,4c]piridin-1-ona como inibidores de hpk1 para o tratamento de câncer
BRPI0712816B1 (pt) compostos de pirrolpirimidina e seu uso
MXPA05005477A (es) Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
CN107922431A (zh) Hpk1抑制剂及其使用方法
JP2017536369A (ja) Ｉｒａｋインヒビターとしてのヘテロアリール化合物及びその使用
CN102947272A (zh) 用作atr激酶抑制剂的2-氨基吡啶衍生物
JP2014141529A (ja) キナーゼのインヒビターとして有用なチアゾールおよびピラゾール
KR20170045748A (ko) 증식성 질병의 치료를 위한 조성물 및 방법
ES2351393T3 (es) Sulfopirroles.
TW201139410A (en) Substituted naphthalenyl-pyrimidine compounds
WO2020135210A1 (zh) 取代芳基化合物及其制备方法和用途
EP1644338A1 (en) 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
CN110467610A (zh) 一种取代嘧啶化合物、其制备方法和用途
CN118434743A (zh) 三环杂环类
HK40043591B (zh) 用作ii型irak抑制剂的杂芳基化合物及其用途

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]